A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing. 

By: Gorm Palmgren - Apr. 19, 2024

#CRISPRMED24

Using dynamic simulations, researchers have discovered that the presence of base mismatches in DNA triggers alterations in the HNH nuclease domain of Cas9. These modifications hinder its conformational activation, indicating a secondary checkpoint after DNA binding but before the cleavage event.

The mechanism appears to act as an additional fidelity check, ensuring only correct DNA sequences are cleaved. EvoCas9, a mutant variant of Cas9, shows even greater sensitivity to mismatches.

EvoCas9 deviates from the typical activation pathway, significantly shifting the HNH domain's positioning and disturbing the enzyme's allosteric communication. This response reinforces the secondary checkpoint's role in maintaining high gene-editing accuracy, suggesting that mutations in evoCas9 preserve and enhance this precision-enhancing mechanism.

The study not only provides a molecular basis for the high fidelity of CRISPR-Cas9 gene editing but also paves the way for the development of more accurate CRISPR technologies in the future.

Zhicheng Zuo led the study at Shanghai University of Engineering Science, and it was published in the Journal of Chemical Theory and Computation on Wednesday. You can read it here.

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNews

News: A Secondary Checkpoint Refines CRISPR Precision
News: A Secondary Checkpoint Refines CRISPR Precision
CLINICAL TRIALS
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Systemic Lupus Erythematosus, SLE, (NCT06255028)
Sponsors:
Century Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine